Abstract
Bortezomib, doxorubicin and dexamethasone (PAD) was evaluated as induction before stem cell transplantation in newly diagnosed multiple myeloma (MM) patients, using bortezomib 1.3 mg/m(2) (PAD1, N = 21) or 1.0 mg/m(2) (PAD2, N = 20). Complete/very good partial response rates with PAD1/PAD2 were 62%/42% postinduction and 81%/53% post-transplant. Progression-free survival (29 vs. 24 months), time to re-treatment (36 vs. 29 months) and overall survival (1 year: 100% vs. 95%; 2 years: 95% vs. 73%) were statistically similar but favoured PAD1 versus PAD2. Toxicity was lower in PAD2; bortezomib dose reduction may help manage toxicities while retaining efficacy. PAD is highly active as front-line induction in MM.
Publication types
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Boronic Acids / administration & dosage
-
Boronic Acids / adverse effects
-
Bortezomib
-
Dexamethasone / administration & dosage
-
Dexamethasone / adverse effects
-
Dose-Response Relationship, Drug
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Follow-Up Studies
-
Hematopoietic Stem Cell Mobilization / methods
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / therapy
-
Peripheral Blood Stem Cell Transplantation
-
Pyrazines / administration & dosage
-
Pyrazines / adverse effects
-
Survival Analysis
-
Treatment Outcome
Substances
-
Boronic Acids
-
Pyrazines
-
Bortezomib
-
Dexamethasone
-
Doxorubicin